

Agilent opens Experience Centre in Hyderabad to supports India's global biopharma ambitions

29 July 2025 | News

Designed to address critical gaps in analytical capabilities and regulatory readiness for biopharma companies



Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, has announced the inauguration of its new Biopharma Experience Centre in Hyderabad, Telangana.

The facility marks a significant investment in India's rapidly growing life sciences ecosystem and reflects Agilent's long-term commitment to advancing biopharmaceutical innovation both locally and globally.

The centre was inaugurated by Duddila Sridhar Babu, Minister for Information Technology, Electronics, Communications, and Industries, Government of Telangana, in the presence of Agilent President and CEO Padraig McDonnell, along with senior leaders from India's pharmaceutical and biopharma sectors.

The new Agilent Biopharma Experience Centre in Hyderabad presents a major opportunity to accelerate the city's leadership in life sciences and healthcare innovation.

Designed to support the full drug development journey, the center brings together advanced lab technologies, expert training, and regulatory-ready workflows to help researchers, scientists, and companies develop high-quality, life-saving medicines faster and more efficiently.

It offers end-to-end solutions across key modalities such as chromatography, mass spectrometry, cell analysis, and lab informatics, allowing companies to simulate real lab environments, test for quality and compliance, and co-create market-ready solutions tailored to both Indian and global needs.

"India is a strategic growth market for Agilent, and Hyderabad is at the forefront of biopharma innovation," said Padraig McDonnell, CEO, Agilent Technologies. "Our future will be defined by continued innovation and a relentless focus on our customers. This new center reflects our commitment to delivering integrated solutions that help bring life-changing therapies

to market faster and more efficiently. It also reinforces our support for the 'Make-in-India' initiative by empowering local innovation, nurturing talent, and enabling scalable, affordable, and sustainable solutions."

The centre is designed to address critical gaps in analytical capabilities and regulatory readiness for biopharma companies. It will serve as a hub for innovation and collaboration, supporting the development of biologics, biosimilars, and precision medicine.

Duddila Sridhar Babu, Minister for Information Technology, Electronics, Communications, and Industries, Government of Telangana said, "Hyderabad has emerged as a complete healthcare and life sciences ecosystem—from drug discovery and clinical trials to world-class hospitals and affordable, high-quality patient care. We are proud to host eight of the top ten global pharma companies, five of India's leading healthcare chains, and over 230 USFDA-approved manufacturing facilities. Contributing nearly one-third of India's pharmaceutical production and 40% of bulk drug exports, Telangana is making a strong impact both nationally and globally. With a strong talent base and a clear focus on innovation, we are building a future-ready healthcare system. The launch of the Agilent Biopharma Experience Centre is a significant milestone in strengthening Telangana's position as a global leader in life sciences, and a valuable addition to our expanding innovation-driven ecosystem."